Regorafenib, which inhibits VEGFR, PDGFR, c-Kit, c-RET, Raf-1, FGFR and Abl, showed in a randomised, controlled, phase II trial a significant improvement in overall survival in patients with recurrent GBM compared to lomustine [43]. Here, KDR is linked to glioblastoma.